Unexpectedly, Gadd and colleagues identified germline CHEK2 variants in 3/117 (2.6%) and 8/651 (1.2%) patients with Wilms tumors in their discovery and validation sets, respectively [220]. This evidence concerns the gene CHEK2 and Wilms tumor.